RxDoctor Payments Data

Marc Rabinowitz, MD

Internal Medicine · Southampton, PANPI 1922111210

Payments from drug & device makers

$11,113in general payments, 2019–2025

Across 708 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$922
  • AbbVie$814
  • Amgen$691
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$624
  • plus $6K from 48 others

What the payments were for

  • Food & beverage$11,085100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,113 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$102,339
Medicare patients
266
Services billed
1,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide176$190,987
OzempicSemaglutide71$87,000
EliquisApixaban93$82,636
JardianceEmpagliflozin77$78,644
FarxigaDapagliflozin Propanediol28$37,495
TrulicityDulaglutide27$34,585
VascepaIcosapent Ethyl45$33,913
JanuviaSitagliptin Phosphate16$23,619
LinzessLinaclotide17$21,762
Repatha SureclickEvolocumab20$21,073
RybelsusSemaglutide17$18,949
Janumet XrSitagliptin Phos/Metformin Hcl17$18,236
Praluent PenAlirocumab15$15,961
NexlizetBempedoic Acid/Ezetimibe13$14,933
GemtesaVibegron12$14,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,122$225,572203 claims
Novo NordiskOzempic, Rybelsus$1,352$105,95088 claims
PfizerEliquis, Paxlovid$356$84,066117 claims
Boehringer IngelheimJardiance$248$78,64477 claims
MerckJanuvia, Janumet Xr$510$41,85633 claims
AstraZenecaFarxiga$922$37,49528 claims
AbbVieLinzess, Synthroid$814$28,98984 claims
GSKArexvy, Anoro Ellipta, Arnuity Ellipta$569$19,13556 claims
Esperion Therapeutics, Inc.Nexlizet$232$14,93313 claims
Sumitomo Pharma America, Inc.Gemtesa$363$14,64512 claims
Sanofi-aventis U.S. LLCAmbien$77$7,60812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Southampton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →